Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL-Reference-Cited by-同舟云学术

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL

Published:2017-05-05 Issue:4 Volume:45 Page:521-528
ISSN:0300-8126
Container-title:Infection
language:en
Short-container-title:Infection

Author:

Madeddu Giordano^ORCID, ,Rusconi Stefano,Cozzi-Lepri Alessandro,Di Giambenedetto Simona,Bonora Stefano,Carbone Alessia,De Luca Andrea,Gianotti Nicola,Di Biagio Antonio,Antinori Andrea

Funder

Bristol-Myers Squibb (Italy)

Gilead Sciences (Italy)

Janssen (Italy)

Merck Sharp and Dohme (Italy)

ViiV (Italy)

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Link

http://link.springer.com/article/10.1007/s15010-017-1018-z/fulltext.html

Reference25 articles.

1. Maagard A, Kvale D. Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms? J Antimicrob Chemother. 2009;64:901–9.

2. Gerschenson M, Brinkman K. Mitochondrial dysfunction in AIDS and its treatment. Mitochondrion. 2004;4:763–77.

3. Blas-García A, Martí-Rodrigo A, Víctor VM, Polo M, Alegre F, Funes HA, Apostolova N, Esplugues JV. The purine analogues abacavir and didanosine increase acetaminophen-induced hepatotoxicity by enhancing mitochondrial dysfunction. J Antimicrob Chemother. 2016;71:916–26.

4. Negredo E, Miró O, Rodríguez-Santiago B, Garrabou G, Estany C, Masabeu A, Force L, Barrufet P, Cucurull J, Domingo P, Alonso-Villaverde C, Bonjoch A, Morén C, Pérez-Alvarez N, Clotet B, MULTINEKA Study Group. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). Clin Infect Dis. 2009;49:892–900.

5. Di Giambenedetto S, Fabbiani M, Colafigli M, Ciccarelli N, Farina S, Sidella L, D’Avino A, Mondi A, Cingolani A, Tamburrini E, Murri R, Navarra P, Cauda R, De Luca A. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study). J Antimicrob Chemother. 2013;68:1364–72.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007–2018;International Journal of Antimicrobial Agents;2023-01

2. Nucleos(t)ide reverse transcriptase inhibitor-sparing regimens in the era of standard 3-drug combination therapies for HIV-1 infection;Global Health & Medicine;2020-12-31

3. Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients;International Journal of STD & AIDS;2020-03-05

4. Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy;Infectious Diseases;2019-11-25

5. Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR study;Journal of Antimicrobial Chemotherapy;2019-07-04